Superbugs on the Rise: Are Hospitals Doing Enough to Stop Them?
"A new study reveals the concerning spread of carbapenem-resistant Pseudomonas aeruginosa in Port Elizabeth hospitals, highlighting the urgent need for better infection control."
In today's world, infections are becoming increasingly difficult to treat. One major reason is the rise of antibiotic-resistant bacteria, often called "superbugs." Among these, Pseudomonas aeruginosa stands out as a tough opponent, especially when it develops resistance to carbapenems, a powerful class of antibiotics used as a last resort. Carbapenem-resistant Pseudomonas aeruginosa (CRPA) poses a significant threat in hospital settings, making infections harder to manage and increasing the risk to patients.
Resistance to carbapenems can arise in several ways, including changes in the bacteria's genes that affect drug entry or removal, and the production of enzymes called carbapenemases that break down the antibiotics. Understanding how these resistance mechanisms spread is crucial for developing effective strategies to combat them.
A recent study investigated the prevalence and genetic characteristics of CRPA in hospitals in Port Elizabeth, South Africa. By identifying the genes responsible for carbapenem resistance and analyzing the genetic relatedness of different CRPA isolates, the researchers aimed to shed light on the extent of the problem and inform infection control efforts.
Hospital Burden and Global AMR
The CDC says it uses multiple data sources and systems to track antimicrobial resistance in the United States and abroad, while WHO’s AMR data portal tracks human-health indicators of national and global responses. WHO warns that without harmonized, immediate global action, common infections could again become fatal in a post-antibiotic era. A 2024 review identifies Pseudomonas aeruginosa and methicillin-resistant organisms among the superbugs commonly found in hospital settings, and reports prolonged hospitalization, prior antibiotic therapy, and patient comorbidities among associated risk factors.
Detection and Treatment Constraints
Culture-based methods remain a prominent approach to detecting antimicrobial resistance, but a 2024 review says current detection techniques can be limited in sensitivity, turnaround time, and their ability to identify all potential resistance genes. The broader response is also constrained by limited antibiotic development: a 2025 review reports that pharmaceutical companies’ discontinuation of research has hindered development of new agents while multidrug-resistant pathogens worsen the problem. Another review identifies inadequate infection control, incorrect antibiotic use, and restricted drug development among factors behind the rapid spread of resistance.
Decoding the Superbug: Genes and Spread
The study, conducted between March and August 2015, examined 234 Pseudomonas aeruginosa isolates from patients in Port Elizabeth hospitals. Of these, 81 were found to be resistant to carbapenems. Further investigation revealed that 15 of these CRPA isolates carried the blavIM-2 gene, which encodes a carbapenemase enzyme.
- Six novel sequence types were identified among the blavIM-2-positive isolates.
- A majority of the isolates (9/15) shared an identical genetic profile, provisionally designated as ST1.
- Five of these ST1 isolates were from patients in the same hospital ward, suggesting a potential environmental reservoir of the bacteria.
- The remaining CRPA isolates, which did not carry the blavIM-2 gene, likely developed carbapenem resistance through other mechanisms.
Recent Findings on Pseudomonas Resistance
A 2026 systematic review and meta-analysis of Pseudomonas aeruginosa in Africa reported a pooled resistance rate of 54.4% across antibiotic classes (95% CI: 45.6–63.0), with resistance reaching 100% for tetracyclines and glycylcyclines. A separate meta-analysis of colistin resistance reported regional P. aeruginosa rates of 20.73% in East Africa, 10.85% in North Africa, and 7.19% in Southern Africa. In a cross-sectional study conducted from March 2021 to March 2022, researchers collected 108 non-duplicate drug-resistant P. aeruginosa isolates from burn patients at Amir-Al-Momenin Hospital in Shiraz, Southern Iran.
Evidence Limits in South African Hospitals
A study of carbapenem-resistant Pseudomonas aeruginosa isolates from patients presenting at hospitals in Port Elizabeth, South Africa, reports diverse sequence types across the hospitals. Its authors say this highlights the occurrence of widespread carbapenem-resistant P. aeruginosa isolates. They also acknowledge limitations in sample size and available clinical information, which constrain how fully the findings can characterize the cases.
Typing Methods and Alternative Strategies
A study of Helicobacter suis found that results from six additional genes placed different isolates into different sequence types, indicating that the study’s multilocus sequence typing scheme had sufficient discriminatory power. Separately, Harvard Health describes judicious antibiotic use as key to controlling antibiotic-resistant bacteria and the rise of superbugs. It also reports that reducing antibiotics in the environment and food chain should reduce their spread to humans, and that phage therapy deployment in animal farming in France is expected to generate more evidence about its efficacy as an alternative to antibiotics.
Fighting Back Against Superbugs: What Can Be Done?
The study's results emphasize the urgent need for improved infection control practices in healthcare facilities. These practices include:
Resistance Profiles and Global Stakes
A 2026 article reports that resistance-related profiles can detect overexpression of efflux pumps, β-lactamase enzymes, porins, and stress-response pathways that contribute directly to resistance phenotypes. Another source reports an estimate of 700,000 deaths globally each year from antibiotic resistance and says the United Nations estimates that superbugs and associated multidrug resistance are projected to ... by 2050; the supplied excerpt does not include the projected figure or outcome. A separate review describes superbugs as pathogens resistant to multiple antibiotics and says antimicrobial resistance threatens to undo decades of medical progress.
Health Consequences and Fewer Treatment Options
A review describes antibiotic resistance as a major global threat to effective treatment of bacterial infections and reports adverse effects on clinical and therapeutic outcomes. The term “superbug” is informal and does not mean a bacterium is invincible; it generally refers to bacteria resistant to multiple antibiotics, leaving doctors with fewer effective treatment options. A 2025 review frames AMR and superbugs through a One Health lens, considering effects on human, animal, and environmental health as well as factors that drive resistance.
<ul> <li>Enhanced hygiene protocols: Frequent and thorough handwashing, surface disinfection, and equipment sterilization.</li> <li>Antibiotic stewardship: Judicious use of antibiotics to minimize the selection pressure that drives resistance.</li> <li>Surveillance and screening: Monitoring the prevalence of CRPA and screening high-risk patients to identify and isolate carriers.</li> <li>Environmental monitoring: Regular testing of hospital environments to detect and eliminate reservoirs of CRPA.</li> </ul>
By implementing these measures, hospitals can help curb the spread of CRPA and protect vulnerable patients from these increasingly challenging infections. Further research is needed to fully understand the transmission dynamics of CRPA and develop novel strategies to combat antibiotic resistance.